Brain Cancer

Adenovirus is Aggressive Against Tumor Xenografts

Published in Gene Therapy Weekly, September 21st, 2000

Collaborating researchers in France and the United States showed that ONYX-015, an E1B-deleted adenovirus, has excellent antitumor activity against human malignant glial brain tumor xenografts.

"Malignant glial brain tumors (MGT), i.e., glioblastomas, anaplastic astrocytomas, and malignant gliomas, remain a major therapeutic challenge in adults and children," stated Gilles Vassal and colleagues from several institutions in France, and Onyx Pharmaceuticals, California. "Since p53 gene is frequently mutated in these tumors, we evaluated the antitumor activity of ONYX-015, an E1B-55 kd gene deleted adenovirus that selectively replicates in and destroys tumor cells...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-09-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry